Hypoxanthine is a pharmacodynamic marker of ischemic brain edema modified by glibenclamide

Brain edema after a large stroke causes significant morbidity and mortality. Here, we seek to identify pharmacodynamic markers of edema that are modified by intravenous (i.v.) glibenclamide (glyburide; BIIB093) treatment. Using metabolomic profiling of 399 plasma samples from patients enrolled in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Irvine, Hannah J., Acharjee, Animesh, Wolcott, Zoe, Ament, Zsuzsanna, Hinson, H.E., Molyneaux, Bradley J., Simard, J. Marc, Sheth, Kevin N., Kimberly, W. Taylor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244997/
https://www.ncbi.nlm.nih.gov/pubmed/35700741
http://dx.doi.org/10.1016/j.xcrm.2022.100654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244997/
https://www.ncbi.nlm.nih.gov/pubmed/35700741
http://dx.doi.org/10.1016/j.xcrm.2022.100654

Ejemplares similares